Adjuvant therapies for colorectal cancer.
The management of colon and rectal cancer has changed dramatically over the last 25 years. The use of adjuvant therapies has become standard practice in locally advanced (stage III and selected stage II) colorectal cancer. Improved surgical techniques, chemotherapeutics and radiotherapy are resulting in higher cure rates and the development of agents targeting proliferative and angiogenic pathways offer further promise. Here we explore risk factors for local and distant recurrence after resection of colon and rectal cancer, and the role of adjuvant treatments. Discussion will focus on the evidence base for adjuvant therapies utilised in colorectal cancer, and the treatment of sub-groups such as the elderly and stage II disease. The role of adjuvant radiotherapy in rectal cancer in reduction of recurrence will be explored and the role and optimal methods for surveillance post-curative resection with or without adjuvant therapy will also be addressed.
Department of Medical Oncology and Clinical Haematology, Western Hospital, Footscray 3011, Victoria, Australia.
Suzanne
S
Kosmider
Lara
L
Lipton
D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000188:drug therapy / Q000532:radiotherapy; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D012307:Risk Factors
D000970:Antineoplastic Agents